Compile Data Set for Download or QSAR
Report error Found 4090 for UniProtKB: P08172
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193784(US9670209, Compound 302 1-((R)-3-((1R,3R,5S)-3-(cy...)
Affinity DataEC50:  25nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193785(US9670209, Compound 303 1-((R)-3-((1R,3R,5S)-3-(2-...)
Affinity DataEC50:  79nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193787(US9670209, Compound 304 1-((R)-3-(3-(Cyclopropylme...)
Affinity DataEC50:  25nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193788(US9670209, Compound 305 1-((R)-3-((1R,3R,5S)-3-(Al...)
Affinity DataEC50:  130nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193789(US9670209, Compound 307 1-((R)-3-(3-(Cyclopropylme...)
Affinity DataEC50:  20nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193790(US9670209, Compound 308 1-((R)-3-(3-(Allyloxy)-8-a...)
Affinity DataEC50:  40nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193791(US9670209, Compound 309 1-((R)-3-(3-(2-Methoxyethy...)
Affinity DataEC50:  32nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193800(US9670209, Compound 311 1-((R)-3-(3-(cyclopropylme...)
Affinity DataEC50:  130nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193802(US9670209, Compound 312 1-((R)-3-(3-(cyclopropylme...)
Affinity DataEC50:  32nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193803(US9670209, Compound 313 1-((R)-3-((1R,3R,58)-3-(2-...)
Affinity DataEC50:  50nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193804(US9670209, Compound 314 1-((R)-3-((1R,3R,58)-3-(cy...)
Affinity DataEC50:  50nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193805(US9670209, Compound 315 1-((R)-3-(3-(cyclobutylmet...)
Affinity DataEC50:  50nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193806(US9670209, Compound 316 1-((R)-3-(3-(cyclopropylme...)
Affinity DataEC50:  250nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193807(US9670209, Compound 317 1-((R)-3-(3-(cyclopropylme...)
Affinity DataEC50:  130nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193808(US9670209, Compound 318 1-((R)-3-((1R,3R,5S)-3-(pr...)
Affinity DataEC50:  63nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193815(US9670209, Compound 319 1-((R)-3-(3-(propoxy)-8-az...)
Affinity DataEC50:  32nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193818(US9670209, Compound 320 1-((R)-3-((1R,3R,58)-3-(2-...)
Affinity DataEC50:  63nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193819(US9670209, Compound 321 1-((R)-3-(3-(cyclopropylme...)
Affinity DataEC50:  7.90nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193820(US9670209, Compound 322 1-((R)-3-((1R,3R,5S)-3-(pr...)
Affinity DataEC50:  79nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193823(US9670209, Compound 323 1-((R)-3-((1R,3R,5S)-3-(2-...)
Affinity DataEC50:  16nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193825(US9670209, Compound 324 1-((R)-3-((1R,3R,5S)-3-(2-...)
Affinity DataEC50:  13nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193787(US9670209, Compound 304 1-((R)-3-(3-(Cyclopropylme...)
Affinity DataEC50:  25nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193788(US9670209, Compound 305 1-((R)-3-((1R,3R,5S)-3-(Al...)
Affinity DataEC50:  130nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM50396483(PLX-4032 | RG 7204 | Ro 5185426 | VEMURAFENIB | US...)
Affinity DataEC50:  1.60E+3nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM193834(US9670209, Comparative compound 2)
Affinity DataEC50:  79nMAssay Description:NIH-3T3 cells were grown in 96-well tissue culture plates to 70% to 80% confluence. Cells were transfected with plasmid DNAs using Superfect Reagent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/7/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280371(ethyl 4-[4- (1-methyl- 1H-imidazol- 2-yl)piperidin...)
Affinity DataEC50: >1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280373(ethyl 4-[4-(1H- pyrrol-1- yl)piperidin- 1yl]azepan...)
Affinity DataEC50:  1.54E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280375(ethyl 4-{4-[5-(4- chlorophenyl)- 1H-pyrazol-1- yl]...)
Affinity DataEC50: >1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280377(ethyl 4-{4-[5-(1- methyl-1H- pyrazol-5-yl)- 1H-pyr...)
Affinity DataEC50: >1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280382(ethyl 4-[4-(5- methyl-1H- pyrazol-1- yl)piperidin-...)
Affinity DataEC50: >1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280386(ethyl 4-[4- (3-methyl- 1H-pyrazol-1- yl)piperidin-...)
Affinity DataEC50: >1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280390(ethyl 4-[4-(5- cyclopropyl- 1H-pyrazol-1- yl)piper...)
Affinity DataEC50:  2.26E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280392(ethyl 4-(4-{5- [1-(propan-2-yl)- 1H-pyrazol-4-yl]-...)
Affinity DataEC50:  680nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280408(ethyl 4-[4-(3- methoxypyridin- 2-yl)piperidin-1- y...)
Affinity DataEC50:  160nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280413(ethyl 4-{4-[2- methoxy-5- (trifluoro- methyl)pyrid...)
Affinity DataEC50:  180nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280422(ethyl 4-{4-[2- (difluoro- methoxy) pyridin-3- yl]p...)
Affinity DataEC50: >1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280425(ethyl 4-{4-[2- (propan-2- yloxy)pyridin-3- yl]pipe...)
Affinity DataEC50: >1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280439(ethyl 4-{4-[5- (trifluoromethyl)- 1H-pyrazol-1- yl...)
Affinity DataEC50: >1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280442(ethyl 4-[4-(6- ethoxypyridin-2- yl)piperidin-1- yl...)
Affinity DataEC50:  2.02E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM280444(ethyl 4-[4- (pyrimidin-2- yl)piperidin-1- yl]azepa...)
Affinity DataEC50: >1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2018
Entry Details
US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM43819(ethyl 4-[2-(thiophen-2-ylcarbonylamino)ethylamino]...)
Affinity DataEC50:  4.89E+4nMAssay Description:Assay Provider: P. Jeffrey Conn Assay Provider Affiliation: Vanderbilt University Grant Title: Discovery of novel allosteric modulators of the M1 mus...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2011
Entry Details
PCBioAssay
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM43820(4-[2-[[(2-chlorophenyl)-oxomethyl]amino]ethylamino...)
Affinity DataEC50:  9.24E+4nMAssay Description:Assay Provider: P. Jeffrey Conn Assay Provider Affiliation: Vanderbilt University Grant Title: Discovery of novel allosteric modulators of the M1 mus...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2011
Entry Details
PCBioAssay
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM43821(4-(2-benzamidoethylamino)-1-piperidinecarboxylic a...)
Affinity DataEC50:  2.80E+4nMAssay Description:Assay Provider: P. Jeffrey Conn Assay Provider Affiliation: Vanderbilt University Grant Title: Discovery of novel allosteric modulators of the M1 mus...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2011
Entry Details
PCBioAssay
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM43822(ethyl 4-[2-[(2-methylbenzoyl)amino]ethylamino]pipe...)
Affinity DataEC50:  9.57E+4nMAssay Description:Assay Provider: P. Jeffrey Conn Assay Provider Affiliation: Vanderbilt University Grant Title: Discovery of novel allosteric modulators of the M1 mus...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2011
Entry Details
PCBioAssay
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM50240694(CHEMBL4067722)
Affinity DataEC50: >1.00E+4nMAssay Description:Agonist activity at human muscarinic acetylcholine receptor M2 expressed in CHO cells assessed as increase in cAMP accumulation after 2 hrs by cAMP-G...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/5/2019
Entry Details Article
PubMed
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM50246706(CHEMBL4071109)
Affinity DataEC50:  9.10E+3nMAssay Description:Agonist activity at human recombinant muscarinic M2 receptor co-expressed with Galphaqi5-HA in African green monkey COS7 cells assessed as IP accumul...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2019
Entry Details Article
PubMed
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM50246711(CHEMBL4091934)
Affinity DataEC50:  1.20E+4nMAssay Description:Agonist activity at human recombinant muscarinic M2 receptor co-expressed with Galphaqi5-HA in African green monkey COS7 cells assessed as IP accumul...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2019
Entry Details Article
PubMed
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM50246733(CHEMBL4100938)
Affinity DataEC50:  220nMAssay Description:Agonist activity at human recombinant muscarinic M2 receptor co-expressed with Galphaqi5-HA in African green monkey COS7 cells assessed as IP accumul...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2019
Entry Details Article
PubMed
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM50246628(CHEMBL4093215)
Affinity DataEC50:  2.30E+3nMAssay Description:Agonist activity at human recombinant muscarinic M2 receptor co-expressed with Galphaqi5-HA in African green monkey COS7 cells assessed as IP accumul...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2019
Entry Details Article
PubMed
TargetMuscarinic acetylcholine receptor M2(Human)
Acadia Pharmaceuticals

US Patent
LigandPNGBDBM50448377(CHEMBL3121473)
Affinity DataEC50:  0.280nMAssay Description:Agonist activity at human recombinant muscarinic M2 receptor co-expressed with Galphaqi5-HA in African green monkey COS7 cells assessed as IP accumul...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2019
Entry Details Article
PubMedPDB3D3D Structure (crystal)
Displayed 1 to 50 (of 4090 total ) | Next | Last >>
Jump to: